Plasma homocysteine is elevated in patients with exfoliation syndrome

American Journal of Ophthalmology

Volumn 136, Issue 1, 2003, Pages 41-46

  Vessani, Roberto M ^a   Ritch, Robert ^a,b   Liebmann, Jeffrey M ^c   Jofe, Mark ^a  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c EAR AND THROAT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ANAMNESIS; ARTICLE; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; EXFOLIATION SYNDROME; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GLAUCOMA; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATORY DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; RISK FACTOR; VITAMIN SUPPLEMENTATION;

EID: 0037678422     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(03)00077-1     Document Type: Article

References (43)

1. Ritch R., Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 45:2001;265-315.
2. Ritch R. Exfoliation syndrome the most common identifiable cause of open-angle glaucoma . J Glaucoma. 3:1994;176-178.
3. Clarke R., Daily L., Robinson K., et al. Hypermocysteinemia an independent risk factor for vascular disease . N Engl J Med. 324:1991;1149-1155.
4. Stampfer M.J., Malinow M.R., Willet W.C., et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.
5. Perry I.J., Refsum H., Morris R.W., et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346:1995;1395-1398.
6. Mitchell P., Wang J.J., Smith W. Association of pseudoexfoliation with increased vascular risk. Am J Ophthalmol. 124:1997;685-687.
7. Linnér E., Popovic V., Gottfries C.G., et al. The exfoliation syndrome in cognitive impairment of cerebrovascular or Alzheimer's type. Acta Ophthalmol Scand. 79:2001;283-285.
8. Leblhuber F., Walli J., Artner-Dworzak E., et al. Hyperhomocysteinemia in dementia. J Neural Transm. 107:2000;1469-1474.
9. Cursiefen C., Hündel A., Schonherr U., Naumann G.O.H. Pseudoexfoliation syndrome in patients with branch and central retinal vein thrombosis. Klin Monatsbl Augenheilkd. 211:1997;17-21.
10. Cursiefen C., Hammer T., Küchle M., et al. Pseudoexfoliation syndrome in eyes with ischemic central retinal vein occlusion. A histopathologic and electron microscopic study. Acta Ophthalmol Scand. 79:2001;476-478.
11. Karjalainen K., Tarkkanen A., Merenmies L. Exfoliation syndrome in enucleated haemorrhagic and absolute glaucoma. Acta Ophthalmol. 65:1987;320-322.
12. Vine A.K. Hyperhomocysteinemia a risk factor for central retinal vein occlusion . Am J Ophthalmol. 129:2000;640-644.
13. Brown B.A., Marx J.L., Ward T.P., et al. Homocysteine a risk factor for retinal venous occlusive disease . Ophthalmology. 109:2002;287-290.
14. Pianka P., Almog Y., Man O., et al. Hyperhomocysteinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology. 107:2000;1588-1592.
15. Weger M., Stanger O., Deutschmann H., et al. Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy. Br J Ophthalmol. 85:2001;803-806.
16. Yildirir A., Aybar F., Tokgozoglu L., et al. Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest. 53:2002;54-58.
17. Nygard O., Nordrehaug J.E., Refsum H., et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337:1997;230-236.
18. Nikfardjam M., Graf S., Hornykewycz S., et al. Homocysteine plasma levels in young patients with coronary artery disease. Relation to history of acute myocardial infarction and anatomical extent of disease. Thromb Res. 103:(Suppl 1):2001;S35-39.
19. Malinow M.R., Nieto F.J., Szklo M., et al. Carotid artery intimal medial wall thickening and plasmahomocysteine in assymptomatic adults the Atherosclerosis Risk in Communities Study . Circulation. 87:1993;1107-1113.
20. den Heijer M., Koster T., Blom H.J., et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 334:1996;759-762.
21. Bostom A.G., Shemin D., Lapane K.L., et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis a case-control study . Atherosclerosis. 114:1995;93-103.
22. Brunelli T., Prisco D., Fedi S., et al. High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. J Vasc Surg. 32:2000;531-536.
23. Schumacher S., Schlötzer-Schrehardt U., Martus P., et al. Pseudoexfoliation syndrome and aneurysms of the abdominal aorta. Lancet. 357:2001;359-360.
24. Hietanen J., Soisalon-Soininen S., Kivelä T., Tarkkanen A. Evaluation of the clinical association between exfoliation syndrome and abdominal aortic aneurysm. Acta Ophthalmol Scand. 80:2002;617-619.
25. Repo L.P., Suhonen M.T., Teräsvirta M.E., Koivisto J.K. Color Doppler imaging of the ophthalmic artery blood flow spectra of patients who have had a transient ischemic attack. Correlations with generalized iris transluminance and pseudoexfoliation syndrome. Ophthalmology. 102:1995;1199-1205.
26. Holló G., Lakatos P., Farkas K. Cold pressor test and plasma endothelin-1 concentration in primary open-angle glaucoma and capsular glaucoma. J Glaucoma. 7:1998;105-110.
27. Janciauskiene S., Krakau T. Alzheimer's peptide a possible link between glaucoma, exfoliation syndrome, and Alzheimer's disease . Acta Ophthalmol Scand. 79:2001;328-329.
28. Brooks A.M.V., Gillies W.E. The development of microneovascular changes in the iris in pseudoexfoliation of the lens capsule. Ophthalmology. 94:1987;1090-1097.
29. Friedburg D., Bischof G. Fluorescein angiographic features of the pseudoexfoliation syndrome. Glaucoma. 4:1982;13-16.
30. Sibour G., Finazzo C., Boles Carenini A. Monolateral pseudoexfoliatio capsulae a study of choroidal blood flow . Acta Ophthalmol Scand. 75:(Suppl 224):1997;13-14.
31. Yuksel N., Karabas V.L., Demirci A., et al. Comparison of blood flow velocities of the extraocular vessels in patients with pseudoexfoliation or primary open-angle glaucoma. Ophthalmologica. 215:2001;424-429.
32. Stamler J.S., Osborne J.A., Jaraki O., et al. Adverse vascular effects of homocystine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 91:1993;308-318.
33. Mujumdar V.S., Aru G.M., Tyagi S.C. Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem. 82:2001;491-500.
34. Torres L., Garcia-Trevijano E.R., Rodriguez J.A., et al. Induction of TIMP-1 expression in rat hepatic stellate cells and hepatocytes a new role for homocysteine in liver fibrosis . Biochim Biophys Acta. 1455:1999;12-22.
35. Garcia-Tevijano E.R., Berasain C., Rodriguez J.A., et al. Hyperhomocysteinemia in liver cirrhosis mechanisms and role in vascular and hepatic fibrosis . Hypertension. 38:2001;1217-1221.
36. Konstas A.G., Marshall G.E., Lee W.R. Immunogold localisation of laminin in normal and exfoliative iris. Br J Ophthalmol. 74:1990;450-457.
37. Marshall G.E., Konstas A.G., Lee W.R. Immunogold fine structural localization of extracellular matrix components in aged human cornea. II. Collagen types V and VI. Graefes Arch Clin Exp Ophthalmol. 229:1991;164-171.
38. Frost P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease a common mutation in methylenetetrahydrofolate reductase . Nat Genetics. 10:1995;111-113.
39. Andersson A., Brattstrom L., Israelsson B., et al. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest. 22:1992;79-87.
40. Desouza C., Keeber M., McNamara D.B., Fonseca V. Drugs affecting homocysteine metabolism impact on cardiovascular risk . Drugs. 62:2002;605-616.
41. Bostom A.G., Eaton C.B., Yanek L., et al. Elevations in total plasma homocysteine in premature coronary artery, cerebrovascular and peripheral vascular disease. Atherosclerosis. 102:1993;121-124.
42. Lobo A., Naso A., Arheart K., et al. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol. 83:1999;821-825.
43. Bostom A.G., Garber C. Endpoints for homocysteine-lowering trials. Lancet. 355:2000;511-512.